Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Norimitsu Shirai"'
Autor:
Britton Boras, Rhys M. Jones, Brandon J. Anson, Dan Arenson, Lisa Aschenbrenner, Malina A. Bakowski, Nathan Beutler, Joseph Binder, Emily Chen, Heather Eng, Holly Hammond, Jennifer Hammond, Robert E. Haupt, Robert Hoffman, Eugene P. Kadar, Rob Kania, Emi Kimoto, Melanie G. Kirkpatrick, Lorraine Lanyon, Emma K. Lendy, Jonathan R. Lillis, James Logue, Suman A. Luthra, Chunlong Ma, Stephen W. Mason, Marisa E. McGrath, Stephen Noell, R. Scott Obach, Matthew N. O’ Brien, Rebecca O’Connor, Kevin Ogilvie, Dafydd Owen, Martin Pettersson, Matthew R. Reese, Thomas F. Rogers, Romel Rosales, Michelle I. Rossulek, Jean G. Sathish, Norimitsu Shirai, Claire Steppan, Martyn Ticehurst, Lawrence W. Updyke, Stuart Weston, Yuao Zhu, Kris M. White, Adolfo García-Sastre, Jun Wang, Arnab K. Chatterjee, Andrew D. Mesecar, Matthew B. Frieman, Annaliesa S. Anderson, Charlotte Allerton
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
The 3CL protease of SARS-CoV-2 is inhibited by PF-00835231 in vitro. Here, the authors show that the prodrug PF-07304814 has broad spectrum activity, inhibiting SARS-CoV and SARS-CoV-2 in mice and its ADME and safety profile support clinical developm
Externí odkaz:
https://doaj.org/article/7c0ac56767d64fb5af7714d7f3a62322
Autor:
Ryan M. Esquejo, Christopher T. Salatto, Jake Delmore, Bina Albuquerque, Allan Reyes, Yuji Shi, Rob Moccia, Emily Cokorinos, Matthew Peloquin, Mara Monetti, Jason Barricklow, Eliza Bollinger, Brennan K. Smith, Emily A. Day, Chuong Nguyen, Kieran F. Geoghegan, John M. Kreeger, Alan Opsahl, Jessica Ward, Amit S. Kalgutkar, David Tess, Lynne Butler, Norimitsu Shirai, Timothy F. Osborne, Gregory R. Steinberg, Morris J. Birnbaum, Kimberly O. Cameron, Russell A. Miller
Publikováno v:
EBioMedicine, Vol 31, Iss , Pp 122-132 (2018)
Dysregulation of hepatic lipid and cholesterol metabolism is a significant contributor to cardiometabolic health, resulting in excessive liver lipid accumulation and ultimately non-alcoholic steatohepatitis (NASH). Therapeutic activators of the AMP-A
Externí odkaz:
https://doaj.org/article/3a6b1a8ecd964eee8550aafb2b27ef05
Autor:
Paul Yenerall, Tae Sung, Kiran Palyada, Jessie Qian, Seda Arat, Steven W Kumpf, Shih-Wen Wang, Kathleen Biddle, Carlos Esparza, Stephanie Chang, Wesley Scott, Walter Collette, Taylor-Symon Winrow, Tim Affolter, Norimitsu Shirai, Stephane Thibault, Julia Wang, Ling Liu, Mary Bauchmann, Jessica Frey, Stefanus Steyn, Aida Sacaan, Allison Vitsky, Youngwook Ahn, Tom Paul, Lawrence Lum, Jon Oyer, Amy Yang, Wenyue Hu
Publikováno v:
Toxicological Sciences.
The degradation tag (dTAG) system for target protein degradation can remove proteins from biological systems without the drawbacks of some genetic methods, such as slow kinetics, lack of reversibility, low specificity, and the inability to titrate do
Autor:
Jean G. Sathish, Siddhartha Bhatt, Jamie K. DaSilva, Declan Flynn, Stephen Jenkinson, Amit S. Kalgutkar, Maggie Liu, Balasubramanian Manickam, Jason Pinkstaff, William J. Reagan, Norimitsu Shirai, Ahmed M. Shoieb, Madhu Sirivelu, Saurabh Vispute, Allison Vitsky, Karen Walters, Todd A. Wisialowski, Lawrence W. Updyke
Publikováno v:
International journal of toxicology. 41(4)
COVID-19 is a potentially fatal infection caused by the SARS-CoV-2 virus. The SARS-CoV-2 3CL protease (Mpro) is a viral enzyme essential for replication and is the target for nirmatrelvir. Paxlovid (nirmatrelvir co-administered with the pharmacokinet
Publikováno v:
Toxicologic pathology. 50(4)
Malignant neuroendocrine tumors were diagnosed in the stomach of two out of sixty female Sprague-Dawley rats treated for 89 weeks with a high dose of a novel, small molecule, cannabinoid-1 antagonist. The tumors were associated with parietal cell atr
Autor:
David A. Beebe, Gregg D. Cappon, Michelle Clasquin, Marc K. Hellerstein, Norimitsu Shirai, William J. Reagan, Zhongyuan Sun, Katherine Hales, Gabriele E. Sonnenberg, Jeffrey A. Pfefferkorn, Theodore J. Schmahai, Nicholas B. Vera, Marcy Matthews, Trenton T. Ross, Clare Buckeridge, Enida Ziso Qejvanaj, Kenneth L. Kelly, Shoh Asano, Santos Carvajal-Gonzalez, William P. Esler, Paul A. Amor, Kelvin W. Li, Arthur Bergman
Publikováno v:
Nature Metabolism. 2:1163-1178
Acetyl-CoA carboxylase (ACC) catalyses the first step of de novo lipogenesis (DNL). Pharmacologic inhibition of ACC has been of interest for therapeutic intervention in a wide range of diseases. We demonstrate here that ACC and DNL are essential for
Autor:
Shawn D. Doran, Jana Polivkova, James A. Southers, Scott W. Bagley, Kim Huard, Dilinie P. Fernando, Manthena V.S. Varma, David A. Beebe, David J. Edmonds, Robert L. Dow, Benjamin A. Thuma, Collin Crowley, William P. Esler, Trenton T. Ross, David A. Tess, Mark Niosi, Amit S. Kalgutkar, Jeffrey A. Pfefferkorn, Norimitsu Shirai, David A. Griffith, Shawn Cabral, Andrew H. Smith, Gregg D. Cappon, Vincent Mascitti, Matthew S. Dowling, Andre Shavnya, David Price, Ayman El-Kattan, Aaron C. Smith, Yi-an Bi, Spiros Liras, Xiaojing Helen Yang, Cathy Préville
Publikováno v:
Journal of Medicinal Chemistry. 63:10879-10896
Preclinical and clinical data suggest that acetyl-CoA carboxylase (ACC) inhibitors have the potential to rebalance disordered lipid metabolism, leading to improvements in nonalcoholic steatohepatitis (NASH). Consistent with these observations, first-
Autor:
Heather Eng, Annaliesa S. Anderson, Norimitsu Shirai, Brandon J. Anson, James Logue, Stuart Weston, Marisa McGrath, Martyn D. Ticehurst, Rebecca E. O’Connor, Michelle Rossulek, Martin Pettersson, Matthew N O' Brien, Jean G. Sathish, Matthew B. Frieman, Emi Kimoto, Jun Wang, R. Scott Obach, Emily I. Chen, Robert Haupt, Yuao Zhu, Thomas F. Rogers, Andrew D. Mesecar, Suman Luthra, Adolfo García-Sastre, Dafydd R. Owen, Rhys M. Jones, Eugene P. Kadar, Chunlong Ma, Rob Kania, Lisa Aschenbrenner, Arnab K. Chatterjee, Charlotte Moira Norfor Allerton, Joseph John Binder, Kevin Ogilvie, Holly L. Hammond, Nathan Beutler, Claire M. Steppan, Jennifer Hammond, Stephen Noell, Romel Rosales, Robert M. Hoffman, Lillis Jonathan Richard, Matthew R. Reese, Stephen W. Mason, Dan Arenson, Malina A. Bakowski, Lawrence W. Updyke, Lorraine F. Lanyon, Kris M. White, Emma K. Lendy, Melanie G. Kirkpatrick, Britton Boras
Publikováno v:
bioRxiv
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
COVID-19 caused by the SARS-CoV-2 virus has become a global pandemic. 3CL protease is a virally encoded protein that is essential across a broad spectrum of coronaviruses with no close human analogs. PF-00835231, a 3CL protease inhibitor, has exhibit
Autor:
Emma K. Lendy, Martyn D. Ticehurst, Robert Steven Kania, Lisa Aschenbrenner, Chuang Ma, Michelle Rossulek, Emily I. Chen, Charlotte Moira Norfor Allerton, Rhys M. Jones, Stephen W. Mason, Kevin Ogilvie, Heather Eng, Dan Arenson, Lorraine F. Lanyon, Abhishek Chatterjee, Rob Haupt, Martin Pettersson, Britton Boras, Eugene P. Kadar, Malina A. Bakowski, Yuao Zhu, Obach Rs, Suman Luthra, Stuart Weston, Joseph John Binder, Lillis, Stephen Noell, Thomas F. Rogers, Dafydd R. Owen, O’Brien Mn, Claire M. Steppan, Lawrence W. Updyke, Jennifer Hammond, Jun Wang, Norimitsu Shirai, Brandon J. Anson, Nathan Beutler, Jean G. Sathish, Melanie G. Kirkpatrick, Annaliesa S. Anderson, James Logue, Matthew B. Frieman, Andrew D. Mesecar, Holly L. Hammond, Robert M. Hoffman, Reese Mr, Marisa McGrath, Rebecca E. O’Connor, Emi Kimoto
Publikováno v:
Nature Communications
COVID-19 caused by the SARS-CoV-2 virus has become a global pandemic. 3CL protease is a virally encoded protein that is essential across a broad spectrum of coronaviruses with no close human analogs. PF-00835231, a 3CL protease inhibitor, has exhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84bedafdf92a23451d3e8b9574a30f85
https://doi.org/10.1101/2020.09.12.293498
https://doi.org/10.1101/2020.09.12.293498
Autor:
Jessica Ward, Jason Barricklow, Chuong Nguyen, Eliza Bollinger, Christopher T. Salatto, Bina Albuquerque, Mara Monetti, Norimitsu Shirai, Emily A. Day, Emily Cokorinos, Kieran F. Geoghegan, Gregory R. Steinberg, Rob Moccia, Matthew Peloquin, Ryan M. Esquejo, Morris J. Birnbaum, Russell A. Miller, Alan C. Opsahl, Brennan K. Smith, Jake Delmore, Kimberly O. Cameron, Timothy F. Osborne, Allan R. Reyes, John M. Kreeger, Lynne Butler, David A. Tess, Amit S. Kalgutkar, Yuji Shi
Publikováno v:
EBioMedicine, Vol 31, Iss, Pp 122-132 (2018)
EBioMedicine
EBioMedicine
Dysregulation of hepatic lipid and cholesterol metabolism is a significant contributor to cardiometabolic health, resulting in excessive liver lipid accumulation and ultimately non-alcoholic steatohepatitis (NASH). Therapeutic activators of the AMP-A